Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Urol J ; 19(4): 268-273, 2022 May 22.
Article in English | MEDLINE | ID: mdl-35598040

ABSTRACT

PURPOSE: To evaluate the efficacy of flexible ureteroscopic lithotripsy (FURSL) based on the concept of enhanced recovery after surgery (ERAS). MATERIALS AND METHODS: This study retrospectively analyzed 435 patients diagnosed with upper urinary calculi between 2017-2020 and categorized them into ERAS (ERAS management) and control groups (traditional management). The operative time, postoperative ambulation time, postoperative hospital stay, the total cost of hospitalization, postoperative complications, and stone removal rate between the two groups were subsequently compared. RESULTS: The FURSL procedure was successfully performed in 427 patients but failed in 4 patients of the ERAS group (n = 216) and 4 of the control group (n = 219). No postoperative complications occurred in either group except for fever and hematuria. There was no significant difference in postoperative fever and stone removal between the two groups (all P > .05). However, patients in the ERAS group had a shorter operative time, shorter postoperative ambulation time, less postoperative severe hematuria, shorter postoperative hospital stay, and lower total cost of hospitalization than those in the control group (all P < .05). CONCLUSION: FURSL, based on the concept of ERAS, is safe and reliable for the treatment of upper urinary calculi, with rapid postoperative recovery and a low cost of hospitalization. It is worthy of clinical promotion.


Subject(s)
Enhanced Recovery After Surgery , Lithotripsy , Urinary Calculi , Hematuria/etiology , Humans , Length of Stay , Lithotripsy/methods , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Retrospective Studies , Treatment Outcome , Ureteroscopy/adverse effects , Ureteroscopy/methods
2.
Opt Express ; 26(18): 23854-23867, 2018 Sep 03.
Article in English | MEDLINE | ID: mdl-30184881

ABSTRACT

Both plasmon-phonon-polariton (SPP-PHP) modes and phonon-polariton (PHP) modes supported in graphene-coated hexagon boron nitride (h-BN) single nanowire are presented. The field distributions of the lowest 5 order modes of SPP-PHP modes supported in graphene-coated hexagon boron nitride nanowire pairs (SPP-PHP-GHNP) and the lowest 5 order modes of PHP modes supported in graphene-coated hexagon boron nitride nanowire pairs (GHNP) are also demonstrated and analyzed, respectively. The results of numerical calculation show that SPP-PHP-GHNP mode 0 owns the strongest confinement and lowest loss among the lowest 5 order modes of SPP-PHP-GHNP. Furthermore, the field enhancement of SPP-PHP-GHNP mode 0 can reach over 105 by controlling the geometry parameters of GHNP. Meanwhile, the influence of tuning the Fermi level of graphene on the field enhancement is also presented in the paper. The proposed structure may improve the development of graphene-h-BN-based optoelectronic devices.

3.
J Cancer Res Clin Oncol ; 140(7): 1067-73, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24525705

ABSTRACT

PURPOSE: A grow body of studies has evaluated the risk of development of urological cancer in systemic lupus erythematosus (SLE) with inconclusive results. To clarify the association, a meta-analysis approach was performed to assess the published evidence on urological cancers and SLE. METHODS: Relevant English electronic databases were systematic searched for published studies characterizing the risk of developing urological cancer as a result of SLE. Standardized incidence rate (SIR) with its 95 % confidence interval (CI) of each study was combined using a fixed-/random-effect model in STATA software. RESULTS: A total of 12 papers including 68366 SLE patients were suitable for meta-analysis. Of these, 9 reported the SIR for prostate cancer, 7 for bladder cancer and 6 for kidney cancer. Summary SIRs were 0.77 (95 % CI 0.69-0.87, P < 0.001); 1.75 (95 % CI 0.94-3.23, P = 0.075) and 2.29 (95 % CI 1.25-4.18, P = 0.007), respectively. Significant heterogeneity was noticed in subgroups of bladder and kidney cancer. No obvious publication bias was detected. CONCLUSIONS: Findings from this meta-analysis indicate that SLE is associated with a decreased risk of prostate cancer and an increased risk of kidney cancer.


Subject(s)
Lupus Erythematosus, Systemic/epidemiology , Urologic Neoplasms/epidemiology , Female , Humans , Incidence , Kidney Neoplasms/epidemiology , Male , Prostatic Neoplasms/epidemiology , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...